Ocular Therapeutix Inc. [OCUL] Unchanged to Outperform at JMP Securities
JMP Securities maintained its Ocular Therapeutix Inc. [NASDAQ:OCUL] rating to the equivalent of Outperform but changed the price target to $30 from $20, in a research note dated December 30, 2020. That figure represents around a 49.40% premium from where the company’s shares closed on Tuesday. Other analysts also revised their coverage, with H.C. Wainwright’s […]
Why Osmotica Pharmaceuticals plc (Nasdaq: OSMT) stock dipped in the premarket?
In the premarket session, Osmotica Pharmaceuticals plc (Nasdaq: OSMT) sank -27.41% to $ 3.93 after The U.S. Food and Drug Administration has issued a Complete Response Letter regarding Osmotica Pharmaceutical’s NDA seeking approval of the investigational agent arbaclofen extended-release tablets to treat the spasticity resulting from multiple sclerosis. Get the hottest stocks to trade every […]
What is different about AstraZeneca PLC’s (AZN) stock today?
AstraZeneca PLC (AZN) shares are in green in the pre-market session Wednesday after a British doctor involved in the approval of Oxford/AstraZeneca’s COVID-19 vaccine said on Wednesday one dose is about 70% effective after 21 days and before the second dose is administered. Get the hottest stocks to trade every day before the market opens […]
What made Conifer Holding Inc’s (CNFR) shares spike in the premarket session?
Conifer Holding Inc (CNFR) stock surged dramatically in the premarket session today. Despite the stock’s recent rally, it should be noted that there were no recent stories regarding the company that could have precipitated such a move. As a result, it might be necessary to mention a momentous event on November 11, 2020, when the […]
What’s driving Hepion Pharmaceuticals, Inc.’s (NASDAQ:HEPA) share price on post-market sessions?
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)stock surged 24.52% to $2.59 in the late hours last night after its Topline results have been announced from the Phase’s low dose cohort 2a ‘AMPITION’ clinical trial of CRV431, a novel cyclophilin inhibitor orally administered once daily.Phase 2a study of CRV431 is continuing at a higher dose of 225 mg, with […]
JMP Securities reiterates Evelo Biosciences Inc. [EVLO] rating to Outperform and sets new price target at $27
JMP Securities maintained its Evelo Biosciences Inc. [NASDAQ:EVLO] rating to the equivalent of Outperform but changed the price target to $27, in a research note dated December 30, 2020. That figure represents around a 139.57% premium from where the company’s shares closed on Tuesday. Some new analysts also started their coverage, with JMP Securities’s analysts […]
TF International launches Fangdd Network Group Ltd. [DUO]’s coverage at Buy with a $18.91 price target
TF International launched its Fangdd Network Group Ltd. [NASDAQ:DUO] rating to the equivalent of Buy and assigned the price target of $18.91, in a research note dated December 30, 2020. That figure represents around a 160.11% premium from where the company’s shares closed on Tuesday. Get the hottest stocks to trade every day before the […]
Daiwa initiates Vertex Pharmaceuticals Incorporated [VRTX] at Outperform and sets price target at $250
Daiwa launched its Vertex Pharmaceuticals Incorporated [NASDAQ:VRTX] rating to the equivalent of Outperform and assigned the price target of $250, in a research note dated December 30, 2020. That figure represents around a 7.07% premium from where the company’s shares closed on Tuesday. Other analysts also revised their coverage, with RBC Capital Mkts’s analysts upgrading […]
Welbilt Inc. [WBT] Stock Gets Reiterated At Baird. It’s Still an Outperform
Baird maintained its Welbilt Inc. [NYSE:WBT] rating to the equivalent of Outperform but changed the price target to $17 from $9, in a research note dated December 30, 2020. That figure represents around a 30.66% premium from where the company’s shares closed on Tuesday. Other analysts also revised their coverage, with Citigroup’s analysts downgrading the […]
AstraZeneca PLC [AZN] Upgraded to Add at AlphaValue
AlphaValue took its AstraZeneca PLC [NASDAQ:AZN] rating to the equivalent of Add from Reduce, in a research note dated December 30, 2020. Other analysts also revised their coverage, with Morgan Stanley’s analysts upgrading the shares from ”an Equal-weight” rating to “an Overweight” rating in a research note to investors issued in early December. Meanwhile, UBS […]